(EMAILWIRE.COM, February 06, 2019 ) The antinuclear antibody test market is segmented into five major disease segments, namely, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and other diseases. Other diseases include Raynaud’s Syndrome, polymyositis, mixed connective tissue disease, drug-induced lupus, and autoimmune hepatitis.

The rheumatoid arthritis segment is expected to account for the largest market share, primarily due to the increasing incidence of rheumatoid arthritis.

Don’t miss out on business opportunities in Antinuclear Antibody Test Market

Target Audience for this Report:

- ANA Testing Instrument Manufacturers and Suppliers
- Clinical Laboratories
- Hospitals
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes Related to Antinuclear Antibody Testing

Download PDF: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218189007

North America is the largest regional segment in the ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the high incidence of autoimmune diseases, growing population and healthcare spending, and growth in the number of individuals covered under medical insurance in the U.S.

The major players in the antinuclear antibody test market are Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).

Read More:
https://www.marketsandmarkets.com/Market-Reports/antinuclear-antibody-test-market-218189007.html